30 sep 25   ixico plc - notice of capital markets day ixico plc | ixi | 13.5 -0.25 (-1.8%) | mkt cap: 12.5m    rns number : 2865b ixico plc 30 september 2025   ixico plc ("ixico", the "company" or the "group")   notice of capital markets day     30 september 2025 ixico plc (aim: ixi) - london, uk. ixico, a global leader in neuroscience imaging and biomarker analytics, using its ai-driven platform to help advance drug development in neurological disorders, today announces it will be hosting a capital markets day for analysts and institutional investors between 14:00 - 17:00 gmt on 30 october 2025 at the offices of cavendish capital markets.   the event will provide the opportunity to hear from ixico's ceo and strengthened senior management team, key customers and industry opinion leaders. the agenda will explore the company's growth strategy and future direction, the neuroscience landscape trends and expansion opportunities for the company, ixico's technology roadmap and a detailed explanation of ixico's ai-driven precision medicine technology platform   existing and prospective retail investors are welcome to join via a live webcast. the facility to submit questions will be available on this platform.   to register your interest please contact cavendish capital markets on +44 (0) 20 7220 0500 or via email ir@cavendish.com   to register for the live webcast investors can sign up to investor meet company for free and add to meet ixico plc via: https://www.investormeetcompany.com/ixico-plc/register-investor     ends   for further information please contact: ixico plc +44 (0) 20 3763 7499 grant nash, chief financial officer james chandler, chief business officer    cavendish capital markets limited (nominated adviser and sole broker)   +44 (0) 20 7220 0500 giles balleny / isaac hooper (corporate finance) nigel birks (healthcare specialist sales) harriet ward (corporate broking) michael f johnson (sales)      about ixico www.ixico.com ixico is a global leader in neuroscience imaging and biomarker analytics, using its proprietary ai-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   as a key part of the global neurological disease research community, the company has built a global reputation and 20-year track record as an end-to-end imaging contract research organisation (icro) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. ixico has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.     the ixico platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as alzheimer's, huntington's and parkinson's.  image data is interrogated by the platform and ixico's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.     this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   mscppucpbupagqb return to news summary

Label: Gestiegen